Pfizer v. Merck: Federal Circuit Rules on Vaccine Patent Validity in Conjugate Vaccine Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Pfizer, Inc. v. Merck Sharp & Dohme Co., Inc. |
| Case Number | 19-1871 (Fed. Cir.) |
| Court | U.S. Court of Appeals for the Federal Circuit |
| Duration | May 2019 – Mar 2024 4 years 10 months |
| Outcome | Affirmed-in-Part, Vacated-in-Part, Remanded-in-Part |
| Patents at Issue | |
| Accused Products | Immunogenic compositions and conjugate vaccines (e.g., pneumococcal, meningococcal) |
Case Overview
The Parties
⚖️ Plaintiff
Global pharmaceutical leader with a robust vaccine IP portfolio, including breakthrough products in pneumococcal and meningococcal vaccine technology.
🛡️ Defendant
A major pharmaceutical company and direct competitor in the vaccine market. Sanofi Pasteur, Inc. and SK Chemicals Co., Ltd. were also named as defendants.
The Patent at Issue
At the heart of this dispute is U.S. Patent No. 9,492,559 B2 (Application No. 14/597,488), directed to immunogenic compositions comprising conjugated capsular saccharide antigens. This patent covers methods and formulations for linking bacterial polysaccharide antigens to carrier proteins — a foundational technique in the development of conjugate vaccines targeting diseases such as pneumococcal pneumonia and meningitis.
- • US 9,492,559 B2 — Immunogenic compositions comprising conjugated capsular saccharide antigens.
Developing a new vaccine?
Check if your vaccine composition might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a three-part verdict: Affirmed-in-Part, Vacated-in-Part, and Remanded-in-Part, with a portion of the appeal also dismissed. This split disposition means some aspects of the lower tribunal’s patentability findings were upheld, others were reversed or set aside, and certain issues were sent back for further proceedings. No specific damages amounts were applicable, as this was a patentability/validity proceeding.
Key Legal Issues
The Invalidity/Cancellation Action confirms this case centered on whether claims of U.S. Patent 9,492,559 B2 should survive validity challenges — likely grounded in obviousness, anticipation, or written description arguments common in vaccine composition patents.
The Federal Circuit’s decision to **vacate in part** is particularly significant, signaling that the lower tribunal applied an incorrect legal standard, improperly construed a claim element, or failed to adequately consider evidence bearing on patentability. In the context of conjugate vaccine technology, obviousness challenges under 35 U.S.C. § 103 are frequently contested. The remand component preserves Pfizer’s opportunity to defend the vacated claims before the lower tribunal under corrected legal standards.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in vaccine technology. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in this technology space
- See which companies are most active in vaccine IP
- Understand claim construction patterns for biologics
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own vaccine or biologic product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Conjugate vaccine compositions
Active Vaccine IP Landscape
Complex patent environment
Design-Around Options
Available for many claims
✅ Key Takeaways
Split Federal Circuit verdicts in validity proceedings require immediate assessment of which claims survived, were vacated, and remain on remand.
Search related case law →Procedural grounds for partial appeal dismissal in multi-defendant cases deserve early strategic attention.
Explore precedents →Obviousness doctrine in conjugate vaccine technology remains actively litigated at the Federal Circuit level.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. 9,492,559 B2, covering immunogenic compositions comprising conjugated capsular saccharide antigens used in vaccine formulations.
The court issued a split decision — affirming in part, vacating in part, and remanding in part — with a portion of the appeal also dismissed, reflecting a nuanced patentability determination.
The mixed outcome reinforces the importance of claim-level validity analysis and layered claim drafting for biologic patents, while confirming that post-grant challenges remain a powerful tool for accused infringers in the vaccine sector.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 19-1871
- U.S. Patent and Trademark Office — Patent 9,492,559 B2
- PACER — Public Access to Court Electronic Records
- Cornell Legal Information Institute — 35 U.S.C. § 103
- PatSnap — IP Intelligence Solutions for Pharma & Biotech
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.